Finance 4h ago 1 min read
AbbVie agreed to acquire Apogee Therapeutics for $135.11 a share in cash, valuing the immunology biotech at about $10.9B. The deal adds zumilokibart, a late-stage IL-13 antibody for atopic dermatitis, and is expected to close in Q3 2026.